Alebund Pharmaceuticals an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the closing of RMB 550 million in Series C financing. Participating investors in this round include a renowned healthcare fund, Yangzhou Guojin Investment Group Co.

Alebund Pharmaceuticals是一家专注于开发肾脏疾病和相关慢性病创新疗法的综合性生物制药公司，宣布关闭5.5亿元人民币的C系列融资。参与本轮投资的投资者包括著名的医疗保健基金扬州国金投资集团有限公司。

LTD, and Kingray Capital..

有限公司和金瑞资本。。

This round of financing will support Alebund in advancing the development and commercial activities of its pipelines in renal disease and to accelerate the development of multiple clinical-stage programs. The fund will support accelerating new drug application (NDA) in China for the best-in-class iron-based phosphate binder AP301 and the conduct of its global pivotal study; the conduct of US/China phase 2 study for the first-in-class pan phosphate transporter inhibitor AP306, and further commercial expansion for Mircera® in China..

这一轮融资将支持Alebund推进其肾脏疾病管道的开发和商业活动，并加速多个临床阶段项目的发展。该基金将支持加速中国最佳铁基磷酸盐粘合剂AP301的新药应用（NDA）及其全球关键研究的开展；美国/中国针对第一类泛磷酸盐转运蛋白抑制剂AP306进行的第二阶段研究，以及Mircera®在中国的进一步商业扩张。。

Chronic kidney disease has become an increasingly serious global public health problem, and its incidence rate is increasing over the years. Focusing on developing innovative treatments for renal diseases, Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal indications, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis (FSGS) and autosomal dominant polycystic kidney disease (ADPKD).

慢性肾脏病已成为日益严重的全球公共卫生问题，其发病率多年来呈上升趋势。Alebund专注于开发肾脏疾病的创新治疗方法，建立了针对一系列肾脏适应症的多样化和平衡的候选药物管道，包括慢性肾病（CKD）/透析并发症，IgA肾病，糖尿病肾病，局灶性节段性肾小球硬化（FSGS）和常染色体显性多囊肾病（ADPKD）。

Alebund has completed the construction of the small molecule production site in Yangzhou and put it into service. Alebund has established a dedicated commercial team in China, focusing on the commercial promotion of Mircera® and launch preparations for future products in its pipeline..

美联邦德已完成扬州小分子生产基地的建设并投入使用。Alebund在中国成立了一个专门的商业团队，专注于Mircera®的商业推广，并为其未来的产品做好准备。。

'The successful closing of Series C financing once again proves the importance of the research and development of new therapies for chronic kidney diseases and the confidence from the market in the Alebund team. ' Dr. Gavin Xia, Co-founder, Chairman, and CEO of Alebund commented, 'We will accelerate the development of Alebund's innovative pipeline globally and expand our commercial footprint in China, to strengthen our influence in renal diseases area, to bring better therapeutic options to patients in China and globally as soon as possible.

“C轮融资的成功结束再次证明了研究和开发慢性肾脏疾病新疗法的重要性，以及市场对Alebund团队的信心。”Alebund联合创始人、董事长兼首席执行官加文·夏博士评论道：“我们将加快Alebund创新管道在全球的发展，扩大我们在中国的商业足迹，加强我们在肾脏疾病领域的影响力，尽快为中国和全球的患者带来更好的治疗选择。

'.

'.

About Alebund Pharmaceuticals

关于Alebund Pharmaceuticals

Alebund was incubated in Shanghai in 2018. It focuses on the discovery, development, production and commercialization of novel therapies primarily for kidney diseases and their complications, as well as other chronic conditions, to bring greater therapeutic options to patients in China and globally.

2018年，Alebund在上海孵化。它专注于主要针对肾脏疾病及其并发症以及其他慢性病的新型疗法的发现，开发，生产和商业化，为中国和全球患者带来更多的治疗选择。

Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal indications, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis (FSGS) and autosomal dominant polycystic kidney disease (ADPKD).

Alebund针对一系列肾脏适应症建立了多样化和平衡的候选药物管道，包括慢性肾病（CKD）/透析并发症，IgA肾病，糖尿病肾病，局灶性节段性肾小球硬化（FSGS）和常染色体显性多囊肾病（ADPKD）。

Alebund's small molecule manufacturing site in Yangzhou has completed construction and has been in service. Alebund has also established a dedicated commercialization team in China, responsible for the commercial promotion of renal products..

美联邦德在扬州的小分子生产基地已完工并投入使用。Alebund还在中国成立了专门的商业化团队，负责肾脏产品的商业推广。。

Source: prnewswire.com

来源：prnewswire.com